| [3H]-MTX |
Specific pharmacokinetic
and metabolic studies
of MTX, radioimmunoassay application; |
(31, 36, 69−81, 83−88) |
| MTX delivery drug system
studies |
(89−103) |
| [75Se]Me-SeCys-“MTX” |
Radioimmunoassay for clinical monitoring of
MTX chemotherapy |
(80, 81) |
| [125I]I-Tyr-MTX |
Radioimmunoassay
for clinical monitoring of
MTX chemotherapy |
(81, 82) |
| [99mTc]Tc-MTX-(glutamine)2
|
BBB permeable prodrug studies |
(104, 105) |
| [99mTc]Tc-MTX-(lysine)2
|
| [99mTc]Tc-MAG2-MTX |
FR-expressing tumor
imaging |
(106−108) |
| [99mTc]Tc-MAG3-MTX |
|
99mTc and 68Ga various complexes of MTX and its derivatives |
FR-expressing
tumor imaging |
(109−114, 116, 117) |
| [111In]In-DTPA-CH2CH2-MTX |
FR-expressing
tumor imaging |
(115) |
| [99mTc]Tc-MTX complex |
Diagnostic application in RA and inflammation |
(122, 123) |
| [99mTc]Tc-MTX-bisphosphonate complex |
Skeletal imaging on rats and rabbits |
(124) |
| [18F]p-fluorobenzene-carbohydrazide-MTX |
PET tracers for FR positive cancers |
(118, 119) |
| [18F]2-fluoropyridine-4-carbohydrazide-MTX |
| [18F]FDG-oxime-carbohydrazide-MTX |
| [111In]In-DTPA-hydrazide-MTX |
In vitro targeting of erythroid
leukemia cells after anti-TFR-mAb-rDHFR pretargeting |
(131) |
| [177Lu]Lu-DOTA-HA-PLGA(MTX) |
Potential
radiosynovectomy application in RA
patients |
(128) |
| [99mTc]Tc-AF488/647-FA-MTX-MWCNTs |
Multimodal multiwalled carbon nanotubes (MWCNTs)
system for theranostic application in FR positive cancers |
(129) |
